Bruce Booth - 06 Jun 2023 Form 4 Insider Report for AVROBIO, Inc. (TECX)

Reporting relationship: Director
Issuer ticker: TECX
Reported as of: 06 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 16:27:43 UTC
Prior SEC filing: 03 Mar 2023
Next SEC filing: 09 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Bruce Booth

Key filing fact

Bruce Booth filed Form 4 for AVROBIO, Inc. (TECX) on 08 Jun 2023.

Key facts

This page summarizes Bruce Booth's Form 4 filing for AVROBIO, Inc. (TECX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 16:27.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVRO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,643
Change %
Price: $0.000000
Shares after: 17,643
Date: 06 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,643
Exercise price: $1.09
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.